Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares?

Core Insights - Chicago Capital, LLC increased its stake in Procept BioRobotics by 999,873 shares, totaling 1,568,845 shares valued at $55.99 million as of quarter-end [1][2] - Procept BioRobotics' stock price was $34.61 as of October 21, 2025, reflecting a 48.57% decline year-over-year and underperforming the S&P 500 by 63.63 percentage points [2] - The company reported a revenue increase of 48% year-over-year in Q2, raising its full-year revenue outlook for 2025 to $325.5 million, a 45% increase over 2024 [9][10] Company Overview - Procept BioRobotics specializes in surgical robotics for urology, focusing on treating benign prostatic hyperplasia (BPH) with its AquaBeam Robotic System [4][5] - The company has a market capitalization of $1.95 billion and a trailing twelve months (TTM) revenue of $274.95 million, with a net income of -$84.15 million [3] Investment Rationale - Chicago Capital's significant increase in investment suggests confidence in Procept BioRobotics' growth potential despite recent stock price declines [7][11] - The company's rapid sales growth and attractive price-to-sales ratio of seven may indicate a compelling investment opportunity [10][11]